Biosimilars Treatment for Multiple Myeloma
Multiple myeloma is a condition wherein plasma cells, which are a type of white blood cells in the bone marrow, become cancerous and start multiplying. This condition can damage the bones, immune system, and kidneys and the treatment for myeloma depends on the stage of cancer. Options include medication, corticosteroids, chemotherapy, and radiation; a stem-cell transplant may also be done. Cost of treatment There have been major advances in the last 15 years in the diagnosis and treatment of multiple myeloma. Overall, survival has remarkably improved during this period due to the research and introduction of new medications. But the costs of treating myeloma are very high, more than other oncology treatments. The cost is amplified in three ways: first, treatment requires a combination of multiple medications; second, treatment is usually done in the form of continuous or maintenance therapy, due to which costs are not temporary but continual; third, as survival through multiple myeloma has remarkably improved, the cumulative cost of care over the lifetime of a patient is very high. The costs for treatment for multiple myeloma can include approximately $150,000 per annum for medication and treatment, and around $100,000 per annum for maintenance and care after initial treatment. These costs not only affect the patient but also society as a whole. Introducing biosimilars to replace biologics – many of whose patents are due to expire – can result in huge savings, projected to be to the tune of $54 billion from 2017 to 2026. Comparing biologics and biosimilars Biologic medicines are transforming cancer treatment by targeting the key path that underlies the mechanism of the disease. They are more active and less toxic in the treatment of cancer than the previous generations of small-molecule medications. The research, manufacturing, and introduction cost of biologics is high, which explains why cancer medication is very expensive.